Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Sinopharm Group Co ( (HK:1099) ).
Sinopharm Group Co. Ltd. announced the unaudited financial results of its subsidiary, China National Medical Device Co., Ltd. (CNMDC), for the nine months ending September 30, 2025. The results showed a slight decline in revenue and operating profit compared to the previous year, with revenue decreasing by 2.41% and operating profit by 10.34%. Despite these declines, the total assets and equity attributable to the parent company increased by 4.01% and 3.86%, respectively, indicating a potential strengthening of the company’s financial position. The net cash flow from operating activities showed a significant improvement, reducing the negative flow by 49.55%, which may suggest better cash management or operational efficiency.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. operates in the healthcare industry, focusing on pharmaceuticals and medical devices. It is a major player in the Chinese market, providing a wide range of healthcare products and services.
Average Trading Volume: 5,544,053
Technical Sentiment Signal: Sell
Current Market Cap: HK$58.38B
For an in-depth examination of 1099 stock, go to TipRanks’ Overview page.